Status:
COMPLETED
ASIA CHOICES CHampix (Varenicline) Observational Investigation in the CEssation of Smoking
Lead Sponsor:
Pfizer
Conditions:
Smoking Cessation
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to describe the characteristics of the smoker who wants to quit and his/her treating physician, in addition to determine the safety and effectiveness of Champix in the rea...
Detailed Description
Sampling Method Description: Patients enrolled after being prescribed Champix for smoking cessation at the sole discretion of treating physician and patient.
Eligibility Criteria
Inclusion
- All patients enrolled should meet the usual prescribing criteria for Champix® as per the local product information and should be entered into the trial at the investigator's discretion
Exclusion
- All patients enrolled should meet the usual prescribing criteria for Champix® as per the local product information and should be entered into the trial at the investigator's discretion
Key Trial Info
Start Date :
February 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2010
Estimated Enrollment :
1373 Patients enrolled
Trial Details
Trial ID
NCT00808015
Start Date
February 1 2009
End Date
July 1 2010
Last Update
May 12 2015
Active Locations (97)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Beijing, Beijing Municipality, China, 100029
2
Pfizer Investigational Site
Beijing, Beijing Municipality, China, 100083
3
Pfizer Investigational Site
Beijing, Beijing Municipality, China, 100191
4
Pfizer Investigational Site
Guangzhou, Guangdong, China, 510080